A2058 Xenograft Rat Model Service for Melanoma

The A2058 Xenograft Rat Model Service for Melanoma delivers a highly metastatic, BRAF-mutant amelanotic melanoma platform that recapitulates the aggressive dissemination and therapeutic resistance patterns characteristic of advanced cutaneous malignancy. Alfa Cytology constructs every A2058 study with surgical precision and molecular rigor, offering reproducible tumor growth kinetics, longitudinal caliper-based volumetrics, and comprehensive histopathological endpoints that empower your preclinical pipeline from target validation through candidate selection.

Overview of A2058 Xenograft Rat Model for Melanoma

The A2058 cell line was established from a lymph node metastasis of a 43-year-old Caucasian male patient with malignant amelanotic melanoma. The cells exhibit an epithelial-like morphology in adherent culture and harbor a BRAF V600D activating mutation within the MAPK pathway, alongside PTEN loss-of-function and mutant p53. This triple-alteration profile generates constitutively elevated phosphorylated ERK and AKT signaling, driving rapid proliferation, matrix invasion, and resistance to conventional cytotoxic agents. A2058 cells further express nerve growth factor (NGF) receptors and laminin-binding proteins, molecular features that underpin their pronounced metastatic capacity and interactions with the peritumoral stroma. In vivo, the line forms robust subcutaneous tumors in immunocompromised hosts with near-universal take rates, while its intrinsic sensitivity profile to BRAF and MEK inhibitors—coupled with its documented capacity to acquire resistance under selective pressure—makes it an indispensable substrate for evaluating next-generation targeted combinations and adaptive therapeutic strategies.

Fig 1. A2058 and A2058-COX-2KO subcutaneous transplant tumor growth curves (individual and aggregate), fluorescence imaging, and tumor formation rate. (Haase-Kohn, Cathleen, et al., 2022)

Beyond its canonical signaling alterations, A2058 harbors a drug-selected subpopulation enriched for melanoma stem-like cells that exhibit slower proliferation, enhanced sphere-forming capacity, and elevated expression of angiopoietin-like 4 (ANGPTL4). These cells demonstrate reduced kinase activation yet retain robust in vivo tumorigenicity even at low inoculum doses, offering a window into the tumor heterogeneity that fuels relapse and therapeutic escape. The model's well-documented response to vemurafenib and its ability to evolve PLX-resistant derivatives under chronic inhibitor exposure provide a dynamic system for studying resistance mechanisms, including MAPK reactivation and PI3K-AKT bypass signaling. Such properties position the A2058 xenograft as a versatile workhorse for melanoma drug discovery spanning targeted small molecules, immunomodulatory antibodies, and oncolytic viral platforms.

Cell Line Information: A2058

The A2058 human malignant melanoma cell line is one of the most extensively utilized models in cutaneous oncology research, distinguished by its amelanotic phenotype, aggressive metastatic behavior, and well-defined oncogenic driver mutations. Isolated from a nodal metastasis and subsequently deposited with international cell culture collections, the line maintains a stable molecular identity that supports reproducible xenograft development across immunodeficient rodent platforms. The table below enumerates the defining characteristics of this line.

Our Services

Alfa Cytology brings specialized dermatologic oncology expertise to every A2058 xenograft engagement, offering subcutaneous implantation with optional Matrigel basement membrane matrix for accelerated engraftment, paired with twice-weekly caliper monitoring, automated tumor volume calculation, and terminal histopathology. Our platform captures melanoma-specific endpoints including HMB-45 and S-100 immunohistochemistry, Ki-67 proliferation indices, and TUNEL apoptosis quantification, delivering audit-ready data packages that support your compound's progression from preclinical proof-of-concept toward IND-enabling toxicology.

Workflow of A2058 Xenograft Rat Model Construction

Construction of an A2058 melanoma xenograft demands meticulous cell culture stewardship, aseptic surgical technique, and standardized volumetric surveillance to ensure reproducible tumor growth and biologically meaningful therapeutic windows. The workflow below outlines the sequence employed to generate reliable A2058-bearing rat cohorts for preclinical evaluation.

1. Cell Line Resuscitation & Expansion. Cryopreserved A2058 cells are thawed rapidly in a 37°C water bath and transferred to pre-warmed EMEM + 10% FBS. Following centrifugation, cells are resuspended in complete medium containing 2 mM L-glutamine and 1% NEAA. Identity is confirmed by STR profiling against the ATCC/ECACC reference database, and mycoplasma negativity is verified by PCR. Cells are expanded to 70–80% confluence with >95% viability prior to inoculum preparation.
2. Recipient Animal Acclimation. Immunodeficient recipient rats (athymic nude or SCID variants) are quarantined and acclimatized for a minimum of 7 days under controlled environmental conditions. Baseline body weights are recorded, and animals are randomized into treatment cohorts using stratified randomization based on body weight to minimize inter-group variance prior to tumor cell injection.
3. Inoculum Preparation & Viability Confirmation. A2058 cells are harvested from exponential-phase cultures using 0.05% trypsin/EDTA, washed twice in sterile PBS, and resuspended at a concentration of 1–2.5 × 10⁷ cells/ml in ice-cold PBS. For enhanced engraftment, cells may be mixed 1:1 with reduced-growth-factor Matrigel basement membrane matrix. Cell viability is reconfirmed by trypan blue exclusion; only single-cell suspensions with >95% viability are approved for in vivo use.
4. Subcutaneous Tumor Cell Injection. Rats are briefly anesthetized with isoflurane inhalation (induction 3–4%, maintenance 1.5–2%). The right flank is shaved and disinfected with povidone-iodine and ethanol. A 25-gauge needle attached to a 1 mL syringe is used to inject 100–200 µL of cell suspension (delivering 2–5 × 10⁶ cells) into the subcutaneous space at the dorsal-lateral aspect of the flank. The injection site is inspected for leakage, and animals are returned to warmed recovery cages.
5. Post-Injection Monitoring & Supportive Care. Animals are observed for acute distress for 2 hours post-injection. Daily health checks include body weight, posture, hydration, and inspection of the injection site for ulceration, infection, or necrosis. Analgesia is provided as needed per IACUC guidelines. Animals are housed in HEPA-filtered biocontainment caging to minimize opportunistic infection risk.
6. Longitudinal Tumor Surveillance. Tumor onset is monitored by palpation every 2–3 days beginning on day 7. Once tumors become palpable, two perpendicular diameters are measured with digital calipers twice weekly. Tumor volume is calculated using the modified ellipsoid formula (length × width² × 0.5). Animals are randomized into treatment arms once tumors reach 50–100 mm³, ensuring uniform baseline tumor burden across cohorts.
7. Endpoint Assessment & Tissue Harvest. Study endpoints are triggered by tumor volume reaching 2,000 mm³ (or institutional limit), ulceration, >20% body weight loss, or moribund condition. Under deep isoflurane anesthesia, animals are humanely euthanized. Tumors are excised, weighed, and bisected for fixation in 10% neutral-buffered formalin and snap-freezing in liquid nitrogen. Regional lymph nodes, lung, and liver are collected for metastasis screening. Specimens undergo histopathology (H&E), immunohistochemistry (HMB-45, S-100, Melan-A, Ki-67, CD31), and molecular profiling of resistance mutations.

Fig 2. A2058 Xenograft Rat Model construction workflow.

Case Study-A2058 Xenograft Rat Model Development

In a recent preclinical engagement, Alfa Cytology established a subcutaneous A2058 xenograft cohort in athymic nude rats to evaluate the anti-tumor activity of a novel BRAF-MEK dual inhibitor administered as monotherapy and in combination with an anti-PD-1 checkpoint antibody. Following flank implantation of 3 × 10⁶ viable A2058 cells mixed with Matrigel, tumors were monitored by twice-weekly caliper measurements until reaching a mean volume of 80 mm³, at which point animals were randomized into vehicle, single-agent, and combination arms. The dual inhibitor was administered orally once daily, while the checkpoint antibody was delivered intraperitoneally twice weekly. Tumor growth curves revealed marked growth delay in the combination cohort relative to either monotherapy, with several animals exhibiting transient tumor regression. At study termination, excised tumors from the combination group showed reduced Ki-67 labeling index, increased cleaved caspase-3 positivity, and diminished CD31 vascular density on immunohistochemical analysis. Pharmacokinetic sampling confirmed target plasma exposures for the small molecule, and flow cytometric analysis of tumor-infiltrating lymphocytes demonstrated enhanced CD8⁺ T-cell infiltration in the anti-PD-1-containing arms. These preclinical observations provided the sponsor with a robust efficacy signal and mechanistic rationale to advance the combination regimen toward formal GLP toxicology studies.

Why Choose Alfa Cytology?

Preclinical melanoma modeling requires more than tumor implantation—it demands an understanding of cutaneous tumor biology, resistance evolution, and the immune microenvironment dynamics that dictate therapeutic outcome. Alfa Cytology distinguishes its A2058 service through the following specialized capabilities:

• Veterinary surgical team experienced in subcutaneous flank implantation with optional Matrigel supplementation, ensuring high tumor take rates, consistent growth kinetics, and minimal perioperative complications.
• Flexible study designs encompassing wild-type A2058, PLX-resistant derivatives, and luciferase-expressing variants to address efficacy, resistance, and real-time tumor tracking objectives within a unified protocol.
• Comprehensive melanoma-focused histopathology suite delivering H&E, HMB-45, S-100, Melan-A, Ki-67, CD31, and TUNEL staining with digital image analysis for objective quantification of proliferation, apoptosis, and angiogenesis.
• Integrated immune profiling capabilities including multi-color flow cytometry of tumor-infiltrating lymphocytes (CD4, CD8, FoxP3, PD-1) and myeloid-derived suppressor cells to capture immunomodulatory drug effects.
• Regulatory-compliant study execution under IACUC-approved protocols with full chain-of-custody documentation, GLP-capable data packages, and audit-ready reports designed to support IND submission and partnership discussions.
• Responsive scientific partnership with biweekly tumor volume reports, real-time data dashboards, and direct access to study directors for adaptive protocol amendments and rapid troubleshooting throughout the engagement.

Contact Us

Whether your melanoma program targets the BRAF-MEK axis, explores immune checkpoint combinations, or seeks to overcome acquired resistance to targeted therapy, Alfa Cytology provides the preclinical infrastructure and dermatologic oncology expertise to move your candidate forward with confidence. Reach out to us today to discuss your A2058 xenograft model requirements, and let our team design a study that generates the definitive preclinical evidence your development strategy demands.

For research use only. Not intended for any clinical use.